Agin-LiebesGZeifmanRLuomaJ, et al. (2022) Prospective examination of the therapeutic role of psychological flexibility and cognitive reappraisal in the ceremonial use of ayahuasca. J Psychopharmacol36(3): 292-305.
2.
de WitHBershadAKGrobC (2022) Challenges in translational research: MDMA in the laboratory versus therapeutic settings. J Psychopharmacol36(3): 249-254.
3.
ErmakovaAODunbarFRuckerJ, et al. (2022) A narrative synthesis of research with 5-MeO-DMT. J Psychopharmacol36(3): 270-291. DOI: 10.1177/02698811211050543.
4.
FaganDSwiftCGTipladyB (1988) Effects of caffeine on vigilance and other performance tests in normal subjects. J Psychopharmacol2(1): 19–25.
5.
FamilyNHendricksPSWilliamsLTJ, et al. (2022) Safety, tolerability, pharmacokinetics, and subjective effects of 50 µg, 75 µg, and 100 µg LSD in healthy participants within a novel intervention paradigm: A proof-of-concept study. J Psychopharmacol36(3): 318-333.
6.
HendricksPSCopesHFamilyN, et al. (2022) Perceptions of safety, subjective effects, and beliefs about the clinical utility of lysergic acid diethylamide in healthy participants within a novel intervention paradigm: Qualitative results from a proof-of-concept study. J Psychopharmacol36(3): 334-343.
7.
KótyukEUrbánRHendeB, et al. (2022) Development and validation of the Reward Deficiency Syndrome Questionnaire (RDSQ-29). J Psychopharmacol36(3): 405-418.
8.
Maples-KellerJLNorrholmSDBurtonM, et al. (2022) A randomized controlled trial of 3,4-methylenedioxymethamphetamine (MDMA) and fear extinction retention in healthy adults. J Psychopharmacol36(3): 364-373.
9.
SchlagAKAdayJSalamI, et al. (2022) Adverse effects of psychedelics: From anecdotes and misinformation to systematic science. J Psychopharmacol36(3): 255-269.
10.
SessaBAdayJSO’BrienS, et al. (2022) Debunking the myth of ‘Blue Mondays’: No evidence of affect drop after taking clinical MDMA. J Psychopharmacol36(3): 356-363.
11.
ShephardABarrettSP (2021) The impacts of caffeine administration, expectancies, and related stimuli on coffee craving, withdrawal, and self-administration. J Psychopharmacol36(3): 374-382.
12.
UthaugMVDavisAKHaasTF, et al. (2022) The epidemiology of mescaline use: Pattern of use, motivations for consumption, and perceived consequences, benefits, and acute and enduring subjective effects. J Psychopharmacol36(3): 306-317.
13.
WießnerIFalchiMMaiaLO, et al. (2022) LSD and creativity: Increased novelty and symbolic thinking, decreased utility and convergent thinking. J Psychopharmacol36(3): 344-355.
14.
WolffMMertensLJWalterM, et al. (2022) The acceptance/avoidance-promoting experiences questionnaire (APEQ): A theory-based approach to psychedelic drugs’ effects on psychological flexibility. J Psychopharmacol36(3): 383-404.
15.
YoungAH (2022) The age of psychedelics. J Psychopharmacol36(1): 3–5.
